Search Ontology:
ChEBI
cabergoline
- Term ID
- CHEBI:3286
- Synonyms
-
- (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide
- (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide
- (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide
- 1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea
- 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea
- 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
- cabergolina
- cabergoline
- cabergolinum
- Definition
- An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.
- References
-
- Beilstein:6020775
- CAS:81409-90-7
- DrugBank:DB00248
- Drug_Central:460
- HMDB:HMDB0014393
- KEGG:C08187
- KEGG:D00987
- LINCS:LSM-3939
- PMID:22075008
- PMID:22336848
- PMID:22740242
- PMID:23110560
- PMID:23743769
- Patent:BE888243
- Patent:US4526892
- VSDB:1830
- Wikipedia:Cabergoline
- Ontology
- ChEBI ( EBI )
- Resources
- CTD
- is a type of
-
- has_role
-
Phenotype
Phenotype resulting from cabergoline
Phenotype where environments contain cabergoline
Phenotype modified by environments containing cabergoline
Human Disease Model